Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer

Inclusion Criteria: * Written informed consent * Histologically confirmed metastatic or locally advanced non-operable colorectal cancer * No prior first line treatment for metastatic colorectal cancer * Age ≥18 years * One or more measurable lesions (≥1cm in diameter with spiral CT scan or ≥2cm with conventional techniques) according to RECIST criteria * ECOG performance status ≤2 * Adequate haematological, renal and hepatic function * Urine protein \<2+ (dipstick) * Life expectancy of ≥12 weeks Exclusion Criteria: * Previous first line treatment for metastatic colorectal cancer(progression \>6 months after the end of adjuvant treatment) * Previous radiotherapy to target lesions * Patients with brain metastases and/or cancerous meningitis * Metastatic infiltration \>50% of the liver parenchyma * Presence or history of other neoplasm except properly treated basal cell skin cancer or in situ cervical carcinoma * Patients participating in interventional clinical trial